olivLaw · US equity research
GRAIL, Inc. GRAL
Services-Medical Laboratories · SIC 8071 · Vertical: Services-Medical Laboratories (SIC 8071)
GRAIL is a healthcare company developing Galleri, a blood test that screens for many cancer types from a single sample and indicates the organ of origin. The company submitted its PMA application to the FDA in January 2026, while commercial sales keep growing, with over 117000 Galleri tests sold in the first half of 2026.
At the close of 02 Nov 2026, GRAIL, Inc. (GRAL) stock was 133.76 USD (−6.74% on the day), with market capitalisation 6.0 bn USD, beta 2.65, 52-week range 43.03–158.92 USD. Latest reported quarter (Q2 2026): revenue of 44.7 m USD (+25.7% YoY), net income of -110.2 m USD, diluted EPS -2.56 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 51.2
- neutral
- Bollinger (20, 2)
- 116.39 – 157.40
- in the lower half of the band · %B 0.42 · band width 30.0%
- SMA 50 / 200
- 113.07 / 78.24
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 8.19 / 8.92
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −6.6% | −2.3% | −4.3 pp | — |
| 3 months | +90.4% | −0.8% | +91.1 pp | — |
| 6 months | +140.3% | +4.7% | +135.6 pp | — |
| Year to date | +56.3% | +10.2% | +46.1 pp | — |
| 1 year | +45.5% | +10.3% | +35.3 pp | −11.7% |
| 3 years | unavailable | +73.0% | unavailable | +63.9% |
| 5 years | unavailable | +61.8% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 28.7 m | 38.3 m | 31.8 m | 35.5 m | 36.2 m | 43.6 m | 40.8 m | 44.7 m |
| Research & development | 78.2 m | 48.3 m | 53.6 m | 46.6 m | 48.6 m | 46.9 m | 48.0 m | 47.4 m |
| Operating income | -183.5 m | -136.9 m | -153.6 m | -158.9 m | -125.3 m | -124.4 m | -135.8 m | -173.8 m |
| Pre-tax income | -172.4 m | -127.0 m | -146.4 m | -152.9 m | -118.7 m | -116.5 m | -127.5 m | -166.7 m |
| Income tax | -46.7 m | -29.9 m | -40.2 m | -38.9 m | -29.7 m | -17.3 m | -34.3 m | -56.5 m |
| Net income | -125.7 m | -97.1 m | -106.2 m | -114.0 m | -89.0 m | -99.2 m | -93.2 m | -110.2 m |
| Diluted EPS | -3.94 | -2.89 ≈ | -3.10 | -3.18 | -2.46 | -2.44 ≈ | -2.29 | -2.56 |
| Operating cash flow | -104.6 m ≈ | -93.5 m | -95.0 m | -77.0 m ≈ | -63.2 m ≈ | -63.8 m | -87.0 m | -80.7 m ≈ |
| Capex | 971.0 k ≈ | 303.0 k | 62.0 k | 369.0 k ≈ | 384.0 k ≈ | 94.0 k | 503.0 k | 432.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 55.6 m | 93.1 m | 125.6 m | 147.2 m |
| Revenue YoY | unavailable | +67.6% | +34.9% | +17.2% |
| Net income | -5.4 bn | -1.5 bn | -2.0 bn | -408.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -173.89 | -47.21 | -63.54 | -11.11 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | -9,719.3% | -1,574.2% | -1,613.9% | -277.5% |
| Free cash flow | -584.2 m | -608.7 m | -582.4 m | -299.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 249.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 2.6 bn USD
- Total assets
- 2.9 bn USD
- Debt / equity
- unavailable
- Current ratio
- 11.97x
- ROE
- -16.1%
- ROA
- -13.8%
- FCF margin
- -203.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 55.6 m | 93.1 m | 125.6 m | 147.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Research & development | 329.6 m | 338.7 m | 322.4 m | 195.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Operating income | -5.4 bn | -1.5 bn | -2.2 bn | -562.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Pre-tax income | -5.4 bn | -1.5 bn | -2.2 bn | -534.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Income tax | -42.3 m | -42.0 m | -135.4 m | -126.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Net income | -5.4 bn | -1.5 bn | -2.0 bn | -408.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Diluted EPS | -173.89 | -47.21 | -63.54 | -11.11 | SEC (XBRL)· 12 Mar 2026verified |
| Weighted average diluted shares | 31.0 m | 31.0 m | 31.9 m | 36.8 m | SEC (XBRL)· 12 Mar 2026verified |
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 241.6 m | 97.3 m | 214.2 m | 249.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Receivables | — | 16.9 m | 20.3 m | 18.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Current assets | — | 156.1 m | 819.9 m | 953.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Property, plant & equipment, net | — | 85.0 m | 69.1 m | 51.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Goodwill | 1.5 bn | 888.9 m | 0 | — | SEC (XBRL)· 05 Mar 2025verified |
| Intangibles (excl. goodwill) | — | 2.7 bn | 2.0 bn | 1.9 bn | SEC (XBRL)· 12 Mar 2026verified |
| Total assets | — | 3.9 bn | 3.0 bn | 2.9 bn | SEC (XBRL)· 12 Mar 2026verified |
| Accounts payable | — | 19.7 m | 4.8 m | 2.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Current liabilities | — | 163.6 m | 76.9 m | 79.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Total liabilities | — | 267.6 m | 479.9 m | 344.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Equity | — | — | 2.5 bn † | 2.6 bn † | SEC (XBRL)· 12 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -561.3 m | -595.8 m | -577.2 m | -299.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Capex | 22.9 m | 12.9 m | 5.2 m | 909.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Free cash flow | -584.2 m ≈ | -608.7 m ≈ | -582.4 m ≈ | -299.9 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Investing cash flow | -22.9 m | -12.9 m | -551.0 m | -85.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Financing cash flow | 604.8 m | 463.8 m | 1.2 bn | 423.3 m | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 6.0 bn USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -236.9% | 13 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 38.4% | 100 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 10.9x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -5.0% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial13/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
GRAIL, Inc. (GRAL). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 147.2 m USD in 2025; YoY growth 17.2%; net margin -236.9%; ROE -16.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 38.4%
- Current ratio: 10.9x
What contradicts it
- Net margin: -236.9%
- FCF yield: -5.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Medical Laboratories (SIC 8071) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRANatera, Inc. | 54.6 bn | — | -12.5% | -7.1% | +35.9% | +59% / +577% |
| LHLabcorp Holdings Inc. | 28.9 bn | 29.2 | 11.4% | 6.9% | +7.2% | +32% / +64% |
| DGXQuest Diagnostics Inc | 27.6 bn | 25.0 | 15.2% | 9.5% | +11.8% | +33% / +83% |
| GHGuardant Health, Inc. | 22.9 bn | — | — | -38.3% | +32.9% | +57% / +578% |
| CAICaris Life Sciences, Inc. | 9.1 bn | 86.7 | 20.1% | 10.6% | +97.0% | +26% / unavailable |
| GRALGRAIL, Inc. | 6.0 bn | — | -16.1% | -236.9% | +17.2% | +46% / unavailable |
| RDNTRadNet, Inc. | 5.8 bn | — | -2.1% | -0.9% | +11.5% | −12% / +120% |
| CDNACaredx, Inc. | 4.5 bn | 35.9 | 33.0% | 25.9% | +13.8% | +381% / +784% |
| VCYTVeracyte, Inc. | 3.9 bn | 35.0 | 8.8% | 20.4% | +16.0% | +4% / +91% |
| FTREFortrea Holdings Inc. | 1.9 bn | — | -12.3% | -2.6% | +1.0% | +58% / −32% |
| PSNLPersonalis, Inc. | 1.7 bn | — | -50.3% | -153.8% | −17.7% | +47% / +930% |
| BLLNBillionToOne, Inc. | 1.2 bn | 148.8 | 26.3% | 9.5% | +100.0% | −15% / unavailable |
| CSTLCastle Biosciences, Inc. | 1.1 bn | — | -4.2% | -5.4% | +3.7% | −13% / +75% |
| FLGTFulgent Genetics, Inc. | 530.8 m | — | -8.0% | -26.0% | +13.8% | −35% / −30% |
| YDESYD Bio Limited | 422.6 m | — | -445.1% | -1,392.6% | +16.9% | −48% / unavailable |
| BDSXBiodesix, Inc. | 229.8 m | — | -540.0% | -27.0% | +24.1% | +163% / −27% |
| XGNExagen Inc. | 203.3 m | — | -113.8% | -26.6% | +19.7% | +6% / +356% |
| SERASera Prognostics, Inc. | 58.3 m | — | -45.0% | -47,475.7% | +5.2% | −40% / +3% |
| AMSAmerican Shared Hospital Services | 8.3 m | — | -7.5% | -5.8% | −0.9% | −42% / −47% |
| MDXHMdxhealth SA | 8.1 m | — | -2,440.4% | -31.1% | +19.8% | −96% / −95% |
| ACONAclarion, Inc. | 5.2 m | — | -59.0% | -10,978.5% | +65.6% | −71% / −100% |
| ADVBAdvanced Biomed Inc. | 3.4 m | 0.4 | 84.8% | 5,231.3% | unavailable | −75% / unavailable |
| BGLCBioNexus Gene Lab Corp. | 2.9 m | — | -33.7% | -82.4% | −21.9% | −78% / −89% |
| BNRBurning Rock Biotech Limited | 0 | — | -10.1% | -10.3% | +9.2% | −53% / +21% |
1- and 3-year price returns: for GRAL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
GRAIL is a healthcare company developing Galleri, a blood test that screens for many cancer types from a single sample and indicates the organ of origin. The company submitted its PMA application to the FDA in January 2026, while commercial sales keep growing, with over 117000 Galleri tests sold in the first half of 2026 2.
SWOT
Strengths
- The company holds one of the largest clinical data sets in genomic medicine, drawn from multiple studies 1. Galleri has rising revenue and commercial volume that grows quarter over quarter 3.
- Partnerships with health systems, employers and insurers provide diversified distribution channels 13. The PATHFINDER 2 studies showed a substantial increase in cancers detected through screening 3.
- The company has sufficient liquidity for operations, with cash and short-term securities reported as of June 30, 2026 3.
Weaknesses
- Net losses are significant and persistent since inception, and gross profit is negative 13. The company expects to keep incurring operating losses over the coming years 2.
- Galleri has not yet received FDA approval and Medicare coverage is not available 1. Commercialisation still depends on the laboratory test rather than an approved product.
- The NHS-Galleri trial did not meet its primary endpoint, which could affect clinical perception and negotiations with payers 1.
Opportunities
- FDA approval and inclusion in USPSTF guidelines could open broad coverage by commercial and public insurers 1. A Medicare coverage timeline is provided in law 1.
- The Samsung partnership could facilitate launch in South Korea and other Asian markets, subject to approvals 2. Single-payer health systems could follow the NHS model 1.
- Results showing fewer late-stage cancers and more early-stage detection could support economic arguments for adoption 13.
Threats
- If the FDA does not approve the PMA or approves with narrow indications, the commercial outlook could change significantly 1. The timing of approval is uncertain.
- Reliance on outside financing and share issuances could dilute shareholders if losses remain high 1. The company used an ATM programme and private placements during the past year 1.
- Real-world results differing from study results could weaken confidence among clinicians and payers 1.
Risks
- FDA approvalhigh
Galleri is not approved and the PMA application is under review. If approval does not come or comes with narrow indications, commercial development could be affected 12.
- NHS-Galleri resultshigh
The trial did not meet its primary endpoint. If payer and clinician perception remains negative, coverage and adoption could be delayed 1.
- Losses and funding needmedium
The company records net losses and needs capital for research and commercialisation. If financing becomes more costly, plans could be scaled back 12.
- Laboratory processingmedium
The move to an industrial-scale version of the test caused delays and added costs. If problems persist, performance and reputation could be affected 1.
- International operationslow
The Samsung partnership depends on regulatory approvals and further conditions. If these are delayed, expansion in Asia could be postponed 2.
Investment thesis
What would need to be true (bull case)
- Galleri sales growth in both the quarter and the first half shows expanding commercial demand 23. If FDA approval comes, coverage could become broad 1.
- Clinical studies showed a substantial rise in cancers detected through screening, and the early-stage results support the public health argument 3.
- Partnerships with Samsung and health plans could extend access to new markets, subject to conditions 23.
What would break the thesis
- Net losses remain large, gross profit is negative, and the company expects losses to continue 13.
- The NHS trial did not meet its primary endpoint, which could limit coverage and adoption in public systems 1.
- Without FDA approval, Galleri remains a laboratory test, and the commercial timeline depends on a decision that is still uncertain 12.
What to watch
- FDA advisory committee decision on the PMA applicationfall 2026
- Final NHS-Galleri trial results and the NHS decisionmid-2026
- Quarterly Galleri test volume and testing revenue trendQ3 2026
- Implementation of the Medicare MCED law and the CMS decision2029
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
GRAIL, Inc. (Nasdaq: GRAL) states its mission as detecting cancer early, when it can be cured 1. Its main product, Galleri, is a multi-cancer test that detects DNA fragments shed into the bloodstream by tumour cells and predicts the organ or tissue of origin. The company was spun off from Illumina in June 2024 1.
Galleri is sold as a laboratory developed test (LDT) in the United States but has not been approved or cleared by the FDA. The PMA application, filed in January 2026, was accepted for review, and the company anticipates an FDA advisory committee in the fall 23. Galleri test revenue grew 24% in the second quarter of 2026 3.
The business depends on clinical study results. The NHS-Galleri trial did not meet its primary endpoint of a statistically significant combined reduction in stage 3 and 4 cancers, but it did show a reduction in stage 4 diagnoses 12. The company has invested heavily in research and development, and net losses remain significant 1.
Segments
Galleri commercial screening
The Galleri test is sold to health systems, employers, digital health platforms, insurers and life insurance providers. In the first half of 2026, Galleri revenue reached 82.5 million dollars, and test volume grew 42% 3. Total company revenue in the second quarter was 44.7 million dollars 3.
Development services and partnerships
The company also earns development services revenue and partnership income. The Samsung partnership for South Korea and possibly other Asian markets could extend international distribution, subject to regulatory approvals 2.
Market context
The market for multi-cancer early detection tests is new and not yet broadly covered. The company says more than 70% of cancer deaths come from cancers without recommended screening 1. A new law from February 2026 creates a Medicare coverage category for these tests, with coverage possible from 2029 1.
Adoption depends on FDA approval, the NHS decision in the United Kingdom and possible inclusion in USPSTF guidelines. If FDA approval is obtained, the company intends to pursue inclusion in USPSTF recommendations, though this may take several years 1.
Trends
- Medicare coverage framework for multi-cancer teststailwind
The February 2026 law could allow Medicare coverage of approved or cleared tests if CMS issues a national coverage determination 1. The timing depends on the CMS process, which could be delayed or more restrictive.
- Pressure from clinical study resultsheadwind
The NHS-Galleri results, without meeting the primary endpoint, could influence the views of clinicians, payers and regulators 1. The company is continuing to analyse the data and could extend follow-up by 6-12 months 1.
- Growth in commercial salestailwind
Galleri test volume grew 35% in the second quarter of 2026, supported by an expanded sales force and partnerships with health plans 23. Continued growth could reduce reliance on outside financing.
- Operating costs and lossesmixed
Net losses and a negative gross profit keep pressure on the balance sheet 13. If volume grows without lowering processing costs, losses could persist.
Competitive position
The sources reviewed do not explicitly name direct competitors. The company does describe standard USPSTF-recommended screenings for breast, cervical, colorectal, lung and prostate cancer as the existing alternative that Galleri would add to 1. It states it is the only MCED test with extensive validation from interventional studies 3.
The company's differentiation rests on targeted methylation analysis, large clinical studies and international agreements. If other multi-cancer test developers obtain comparable data, competitive pressure could rise 1.
- Standard USPSTF single-cancer screening tests
Screening for breast, cervical, colorectal, lung and prostate cancer is the existing alternative that Galleri is meant to complement 1.
- Other multi-cancer test developers
The sources do not identify them. Potential competitors could emerge if comparable results are published.
- Public health systems
The UK NHS decides whether to implement Galleri; other single-payer systems could follow the same model 1.
- Symptom-based clinical diagnosis
Late diagnosis once symptoms appear remains the predominant practice, which the company treats as a public health problem 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Biocon Chair: AI in Clinical Trials Is the Holy GrailBloomberg Markets · 15 Oct 2026 · EN
- Tax-Slashing ‘Holy Grail’ Popularized by AQR Dealt IRS WarningBloomberg Markets · 28 Sept 2026 · EN
- STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risksSTAT News · 23 Sept 2026 · EN
- Grail's cancer blood test faces high-stakes FDA reviewMedical Xpress · 23 Sept 2026 · EN
- A Step in the Search for the Elusive Holy Grail of Early Detection of CancerNew England Journal of Medicine · 22 Sept 2026 · EN
- AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s MarketYahoo Finance — News · 21 Sept 2026 · EN
- STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulatorsSTAT News · 21 Sept 2026 · EN
- AI, ex-Soviet engineers, and the Holy Grail of rocketryHacker News · 31 Aug 2026 · EN
- Musk Aiming For 'Holy Grail of Space Flight' in Reusability, Says Loren GrushBloomberg Markets · 12 Jun 2026 · EN
SEC filings
- Quarterly report06 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report22 Jun 2026Shareholder vote
- Current report01 Jun 2026Departure or appointment of officers · Other events · Financial statements and exhibits
- Quarterly report07 May 2026
- Current report05 May 2026Results of operations · Financial statements and exhibits
- Proxy statement28 Apr 2026
- Annual report12 Mar 2026
- Current report19 Feb 2026Results of operations · Other events · Financial statements and exhibits
- Current report12 Jan 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / GRAIL, Inc. · 12 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / GRAIL, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / GRAIL, Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.